The CASP6 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the human HT29 colorectal adenocarcinoma cell line, engineered for targeted disruption of the CASP6 gene. This loss-of-function model enables researchers to dissect the role of the executioner caspase-6 in apoptotic signaling and colorectal cancer biology. The polyclonal format provides a heterogeneous knockout pool, preserving genetic diversity and reducing clonal artifacts, suitable for functional genomics studies and drug screening applications.
HT29 is a well-established epithelial cell line originally isolated from a human colorectal adenocarcinoma, widely used as a model for intestinal epithelium and colorectal cancer research. These cells retain epithelial morphology, express characteristic markers, and exhibit auxotrophic dependencies, making them a robust platform for investigating tumorigenesis, apoptosis resistance, and therapeutic responses. Their adherent growth and reproducible behavior facilitate high-throughput assays and mechanistic dissection of oncogenic pathways.
CASP6 encodes caspase-6, an executioner cysteine protease activated downstream of initiator caspases such as caspase-8 and caspase-9 upon apoptotic stimuli. Once proteolytically cleaved, active caspase-6 mediates nuclear envelope disassembly by cleaving lamin A/C and other structural substrates, including cytokeratin 18, PARP, and gelsolin. Caspase-6 is regulated by upstream signals through death receptors (Fas/FasL, TNF), mitochondrial cytochrome c release, and the apoptosome complex containing APAF-1 and caspase-9. Its activity is modulated by interaction with caspase-3 and inhibition by XIAP, positioning it at a pivotal node in both intrinsic and extrinsic apoptotic pathways.
In the context of HT29 colorectal cancer cells, CASP6 knockout provides a valuable model to interrogate apoptosis evasion mechanisms and drug resistance. Colorectal cancers often downregulate apoptotic machinery, and caspase-6 deficiency may compromise cell death signaling, allowing tumor progression. This polyclonal knockout population enables the study of how loss of caspase-6 function influences sensitivity to chemotherapeutics, death receptor agonists, and targeted agents. Additionally, it can be used to model the interplay between apoptosis and inflammatory pathways relevant to colorectal cancer and inflammatory bowel diseases.
Researchers can employ these CASP6 knockout HT29 cells in a broad spectrum of assays including western blotting and caspase-6 activity assays to confirm protein ablation and functional deficiency, annexin V/PI apoptosis assays and flow cytometry to quantify cell death responses, and colony formation, proliferation, and migration assays to assess oncogenic phenotypes. The model is particularly suited for investigating apoptosis mechanism studies, cancer drug resistance, colorectal cancer progression, and caspase-6 functional genomics, with potential applications in neuroprotection studies as well. For further information, please contact Ascent Research.
